Immunogenicity and Safety of Hepatitis B Vaccine With a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People With Human Immunodeficiency Virus (HIV)

Kristen M. Marks,Minhee Kang,Triin Umbleja,Anchalee Avihingsanon,Patcharaphan Sugandhavesa,Andrea L. Cox,Karen Vigil,Hugo Perazzo,Jennifer C. Price,Leolin Katsidzira,Christina Vernon,Beverly Alston-Smith,Kenneth E. Sherman

CLINICAL INFECTIOUS DISEASES（2023）

引用 0|浏览20

暂无评分

摘要

In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.

查看译文

关键词

hepatitis B, vaccine, HIV, HepB-CpG, Heplisav-B

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要